Adaptimmune Therapeutics

$4.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-2.18%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, and ETFs commission-free!

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

CEO
Adrian Rawcliffe
Employees
462
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
767.67M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
600.94K
High Today
$5.03
Low Today
$4.81
Open Price
$5.03
Volume
756.76K
52 Week High
$13.40
52 Week Low
$3.20

ADAP Earnings

-$0.32
-$0.21
-$0.11
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 13, Pre-Market

You May Also Like

NVFY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure